{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:45:35Z","timestamp":1792003535722,"version":"4.4.0"},"reference-count":259,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"am","delay-in-days":302,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["P01HL147835"],"award-info":[{"award-number":["P01HL147835"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["5P42ES010337"],"award-info":[{"award-number":["5P42ES010337"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["5UL1TR001442"],"award-info":[{"award-number":["5UL1TR001442"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-18-2-0026"],"award-info":[{"award-number":["W81XWH-18-2-0026"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["K23DK119460"],"award-info":[{"award-number":["K23DK119460"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K23DK119460"],"award-info":[{"award-number":["K23DK119460"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR073324"],"award-info":[{"award-number":["R01AR073324"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK106419"],"award-info":[{"award-number":["R01DK106419"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK124318"],"award-info":[{"award-number":["R01DK124318"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30DK120515"],"award-info":[{"award-number":["P30DK120515"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK061734"],"award-info":[{"award-number":["U01DK061734"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK121378"],"award-info":[{"award-number":["R01DK121378"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.semarthrit.2023.152165","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T13:09:30Z","timestamp":1674047370000},"page":"152165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review"],"prefix":"10.1016","volume":"59","author":[{"given":"Kelly","family":"Torosian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8691-0598","authenticated-orcid":false,"given":"Esha","family":"Lal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeral","family":"Ajmera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1951-9411","authenticated-orcid":false,"given":"Monica","family":"Guma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2023.152165_bib0001","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0002","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","article-title":"Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics","volume":"69","author":"Mease","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0003","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","article-title":"Psoriasis prevalence in adults in the United States","volume":"157","author":"Armstrong","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0004","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0005","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0006","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","article-title":"The natural history of nonalcoholic fatty liver disease: a population-based cohort study","volume":"129","author":"Adams","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0007","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% Rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0008","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40618-022-01755-0","article-title":"Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies","volume":"45","author":"Bellinato","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0009","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2013.5015","article-title":"Psoriasis severity and the prevalence of major medical comorbidity: a population-based study","volume":"149","author":"Yeung","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0010","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2009.04.020","article-title":"Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis","volume":"51","author":"Gisondi","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0011","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0012","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0013","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/biomedicines9070762","article-title":"Role of leptin in non-alcoholic fatty liver disease","volume":"9","author":"Jim\u00e9nez-Cortegana","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0014","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/ijms17020217","article-title":"Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis?","volume":"17","author":"Mantovani","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0015","first-page":"43","article-title":"Nonalcoholic fatty liver disease and psoriasis","volume":"8","author":"Prussick","year":"2015","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0016","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jaad.2013.10.044","article-title":"Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study","volume":"70","author":"van der Voort","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0017","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3945\/ajcn.2008.26427","article-title":"Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial","volume":"88","author":"Gisondi","year":"2008","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0018","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.3390\/ijerph15071486","article-title":"Psoriasis severity\u2014a risk factor of insulin resistance independent of metabolic syndrome","volume":"15","author":"Polic","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0019","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-4632.2009.04358.x","article-title":"Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis","volume":"49","author":"Karadag","year":"2010","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0020","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/j.1365-2133.2007.08190.x","article-title":"Psoriasis patients show signs of insulin resistance","volume":"157","author":"Boehncke","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0021","doi-asserted-by":"crossref","first-page":"610","DOI":"10.7150\/ijbs.29599","article-title":"Obesity, nonalcoholic fatty liver disease and adipocytokines network in promotion of cancer","volume":"15","author":"Divella","year":"2019","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0022","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0023","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.1840120505","article-title":"Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors","volume":"12","author":"Wanless","year":"1990","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0024","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1467-789X.2005.00159.x","article-title":"Adiponectin: action, regulation and association to insulin sensitivity","volume":"6","author":"Lihn","year":"2005","journal-title":"Obes Rev"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0026","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2183\/pjab.86.131","article-title":"Establishment of a concept of visceral fat syndrome and discovery of adiponectin","volume":"86","author":"Matsuzawa","year":"2010","journal-title":"Proc Jpn Acad Ser B"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1172\/JCI200317797","article-title":"The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice","volume":"112","author":"Xu","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0028","doi-asserted-by":"crossref","first-page":"25569","DOI":"10.1074\/jbc.M109.019786","article-title":"Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10","volume":"284","author":"Folco","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0029","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1038\/ncomms8687","article-title":"Adiponectin regulates psoriasiform skin inflammation by suppressing IL-17 production from \u03b3\u03b4-T cells","volume":"6","author":"Shibata","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0030","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bbrc.2004.08.145","article-title":"Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes","volume":"323","author":"Wolf","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0031","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000481882","article-title":"Serum leptin, resistin, and adiponectin concentrations in psoriasis: a meta-analysis of observational studies","volume":"233","author":"Kyriakou","year":"2017","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0032","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jdermsci.2009.05.008","article-title":"Circulating levels of adiponectin, oxidized LDL and C-reactive protein in Portuguese patients with psoriasis vulgaris, according to body mass index, severity and duration of the disease","volume":"55","author":"Coimbra","year":"2009","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0033","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/nm788","article-title":"Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase","volume":"8","author":"Yamauchi","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0034","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1365-2265.2006.02527.x","article-title":"Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2006","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0035","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jhep.2011.12.011","article-title":"Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up","volume":"56","author":"Zelber-Sagi","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0036","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1006\/cimm.1999.1490","article-title":"Human leptin stimulates proliferation and activation of human circulating monocytes","volume":"194","author":"Santos-Alvarez","year":"1999","journal-title":"Cell Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0037","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2527\/1998.7651405x","article-title":"The biology of leptin: a review","volume":"76","author":"Houseknecht","year":"1998","journal-title":"J Anim Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0038","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.mehy.2005.11.050","article-title":"Chronic inflammation in psoriasis and obesity: implications for therapy","volume":"67","author":"Hamminga","year":"2006","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0039","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/exd.12162","article-title":"Leptin induces secretion of pro-inflammatory cytokines by human keratinocytes in vitro\u2013a possible reason for increased severity of psoriasis in patients with a high body mass index","volume":"22","author":"Xue","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0040","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1365-2133.2008.08456.x","article-title":"Psoriasis is associated with increased levels of serum leptin","volume":"158","author":"Wang","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0041","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1111\/j.1365-2133.2008.08742.x","article-title":"Serum leptin levels, skin leptin and leptin receptor expression in psoriasis","volume":"159","author":"Cerman","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0042","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/db09-1918","article-title":"Leptin deficiency causes insulin resistance induced by uncontrolled diabetes","volume":"59","author":"German","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0043","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/jhep.2001.26518","article-title":"Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals","volume":"34","author":"Ikejima","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0044","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1053\/gast.2002.33369","article-title":"Leptin and liver fibrosis: a matter of fat","volume":"122","author":"Marra","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0045","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3350\/cmh.2018.0011","article-title":"The Association of leptin with severity of non-alcoholic fatty liver disease: a population-based study","volume":"24","author":"Rotundo","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.gene.6364351","article-title":"Psoriasis: genetic associations and immune system changes","volume":"8","author":"Liu","year":"2007","journal-title":"Genes Immun"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0047","doi-asserted-by":"crossref","first-page":"19867","DOI":"10.3390\/ijms141019867","article-title":"Immunological mechanisms in the pathophysiology of non-alcoholic steatohepatitis","volume":"14","author":"Vonghia","year":"2013","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0048","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200519010-00006","article-title":"TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis","volume":"19","author":"Tobin","year":"2005","journal-title":"BioDrugs"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0049","first-page":"235","article-title":"Effects of tumor necrosis factor \u03b1 inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus","volume":"97","author":"Al-Mutairi","year":"2016","journal-title":"Cutis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0050","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/13813450802181047","article-title":"Insulin resistance associated to obesity: the link TNF-alpha","volume":"114","author":"Nieto-Vazquez","year":"2008","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0051","first-page":"119","article-title":"Tumor necrosis factor-\u03b1: life and death of hepatocytes during liver ischemia\/reperfusion injury","volume":"13","author":"Shuh","year":"2013","journal-title":"Ochsner J"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0052","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.20283","article-title":"Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway","volume":"40","author":"Feldstein","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0053","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1572-0241.2007.01709.x","article-title":"Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment","volume":"103","author":"Carter-Kent","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0054","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/jhep.2001.29628","article-title":"Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients","volume":"34","author":"Crespo","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0055","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0056","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0057","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0058","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1038\/jid.2013.237","article-title":"IL-17 and TNF synergistically modulate cytokine expression while suppressing melanogenesis: potential relevance to psoriasis","volume":"133","author":"Wang","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0059","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s13075-014-0426-z","article-title":"Heterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?","volume":"16","author":"van Baarsen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0060","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar3781","article-title":"Functional role of IL-22 in psoriatic arthritis","volume":"14","author":"Mitra","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0061","doi-asserted-by":"crossref","first-page":"E530","DOI":"10.3390\/ijms19020530","article-title":"Role of the IL-23\/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints","volume":"19","author":"Boutet","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0062","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.autrev.2016.09.015","article-title":"Are psoriasis and psoriatic arthritis the same disease? The IL-23\/IL-17 axis data","volume":"16","author":"Sakkas","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0063","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1136\/annrheumdis-2013-204782","article-title":"IL-17A gene transfer induces bone loss and epidermal hyperplasia associated with psoriatic arthritis","volume":"74","author":"Adamopoulos","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0064","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ccell.2016.05.020","article-title":"Metabolic inflammation-associated IL-17A causes non-alcoholic steatohepatitis and hepatocellular carcinoma","volume":"30","author":"Gomes","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0065","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.bbadis.2017.01.027","article-title":"Interleukin-17A exacerbates high-fat diet-induced hepatic steatosis by inhibiting fatty acid \u03b2-oxidation","volume":"1863","author":"Shen","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0066","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41423-018-0029-8","article-title":"Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects","volume":"16","author":"Tang","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0067","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1074\/jbc.M510660200","article-title":"Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis","volume":"281","author":"Malhi","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0068","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20150405","article-title":"The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice","volume":"130","author":"Rolla","year":"2016","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0069","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.06.045","article-title":"c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice","volume":"137","author":"Kodama","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0070","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.4049\/jimmunol.1400861","article-title":"IL-17A enhances the expression of profibrotic genes through upregulation of the TGF-\u03b2 receptor on hepatic stellate cells in a JNK-dependent manner","volume":"193","author":"Fabre","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0071","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.immuni.2004.07.007","article-title":"IL-22 increases the innate immunity of tissues","volume":"21","author":"Wolk","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0072","first-page":"1092","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0073","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0074","doi-asserted-by":"crossref","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247149","article-title":"The impact of genetic background and sex on the phenotype of IL-23 induced murine spondyloarthritis","volume":"16","author":"Haley","year":"2021","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0076","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","article-title":"Interleukin-23\u2013Dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice","volume":"68","author":"Reinhardt","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0077","doi-asserted-by":"crossref","first-page":"7590","DOI":"10.1038\/s41598-018-25988-3","article-title":"\u03b3\u03b4TCR regulates production of interleukin-27 by neutrophils and attenuates inflammatory arthritis","volume":"8","author":"Bouchareychas","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0078","doi-asserted-by":"crossref","first-page":"5531","DOI":"10.4049\/jimmunol.0904091","article-title":"IL-22 induces an acute-phase response","volume":"185","author":"Liang","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0079","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep.20184","article-title":"Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation","volume":"39","author":"Radaeva","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0080","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hep.24339","article-title":"In vivo consequences of liver-specific interleukin-22 expression in mice: implications for human liver disease progression","volume":"54","author":"Park","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0081","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0082","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1523-1747.ep12477880","article-title":"Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis","volume":"97","author":"Neuner","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0083","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0923-1811(96)00562-2","article-title":"Role of increased production of monocytes TNF-alpha, IL-1beta and IL-6 in psoriasis: relation to focal infection, disease activity and responses to treatments","volume":"14","author":"Mizutani","year":"1997","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0084","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nature04753","article-title":"Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells","volume":"441","author":"Bettelli","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0085","series-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis - Belasco -","year":"2015"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0086","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/1573397113666170427125918","article-title":"Synovial fluid and serum concentrations of inflammatory markers in rheumatoid arthritis, psoriatic arthritis and osteoarthitis: a systematic review","volume":"13","author":"Altobelli","year":"2017","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0087","first-page":"413","article-title":"Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters","volume":"14","author":"Spadaro","year":"1996","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0088","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/713618","article-title":"Pathological role of interleukin-6 in psoriatic arthritis","volume":"2012","author":"Ogata","year":"2012","journal-title":"Arthritis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0089","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1111\/j.1572-0241.2007.01774.x","article-title":"Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis","volume":"103","author":"Wieckowska","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0091","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","article-title":"Highly effective new treatments for psoriasis target the IL-23\/Type 17 T cell autoimmune axis","volume":"68","author":"Kim","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0092","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/2040622318759282","article-title":"Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment","volume":"9","author":"Chan","year":"2018","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0093","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrrheum.2015.53","article-title":"The IL-23-IL-17 axis in inflammatory arthritis","volume":"11","author":"Lubberts","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0094","series-title":"Tissue-Resident memory phenotype and function of synovial interleukin-17A+CD8+ T cells in psoriatic arthritis - Steel -","year":"2020"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-2249.2011.04471.x","article-title":"Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease","volume":"166","author":"Tang","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0096","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0097","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0098","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2337\/diabetes.54.3.603","article-title":"Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes","volume":"54","author":"Petersen","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0099","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0100","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0101","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: a randomized clinical study","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0102","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/bjd.12735","article-title":"Diet and physical exercise in psoriasis: a randomized controlled trial","volume":"170","author":"Naldi","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0103","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1517\/14712598.2014.900541","article-title":"The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial","volume":"14","author":"Al-Mutairi","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0104","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0105","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clnu.2013.08.014","article-title":"Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease","volume":"33","author":"Kontogianni","year":"2014","journal-title":"Clin Nutr"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0106","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1001\/jamadermatol.2018.2127","article-title":"Association between mediterranean anti-inflammatory dietary profile and severity of psoriasis: results from the NutriNet-Sant\u00e9 cohort","volume":"154","author":"Phan","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0107","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1210\/en.2007-0132","article-title":"Infliximab restores glucose homeostasis in an animal model of diet-induced obesity and diabetes","volume":"148","author":"Ara\u00fajo","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0108","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1677\/JOE-07-0234","article-title":"Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet","volume":"194","author":"Barbuio","year":"2007","journal-title":"J Endocrinol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10753-007-9053-z","article-title":"The treatment with antibody of TNF-alpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine- and choline-deficient diet","volume":"31","author":"Koca","year":"2008","journal-title":"Inflammation"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2023.152165_bib0110","first-page":"167","article-title":"A comparison of the effects of infliximab, adalimumab, and pentoxifylline on rats with non-alcoholic steatohepatitis","volume":"25","author":"Yalcin","year":"2014","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0111","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1136\/ard.2009.116194","article-title":"Hepatoprotective effect of tumour necrosis factor alpha blockade in psoriatic arthritis: a cross-sectional study","volume":"69","author":"Seitz","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0112","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00535-012-0678-9","article-title":"The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis","volume":"48","author":"Campanati","year":"2013","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0113","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0114","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/jdv.16004","article-title":"Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients","volume":"34","author":"Gerdes","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0115","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1021\/acsami.8b19717","article-title":"Targeted interleukin-22 gene delivery in the liver by polymetformin and penetratin-based hybrid nanoparticles to treat nonalcoholic fatty liver disease","volume":"11","author":"Zai","year":"2019","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0116","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2010.03.004","article-title":"Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22","volume":"53","author":"Yang","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0117","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0118","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt.1164","article-title":"Randomized Phase I Healthy Volunteer Study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury","volume":"105","author":"Rothenberg","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0119","series-title":"A single dose study of the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity Of ILV-095 administered subcutaneously to subjects with psoriasis","year":"2017"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0120","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/s41467-022-29174-y","article-title":"Autophagy impairment in liver CD11c+ cells promotes non-alcoholic fatty liver disease through production of IL-23","volume":"13","author":"Galle-Treger","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A Phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U Trial)","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0122","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ad.2015.02.002","article-title":"Liver injury in psoriasis patients receiving ustekinumab: a retrospective study of 44 patients treated in the clinical practice setting","volume":"106","author":"Llamas-Velasco","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0123","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/art.39700","article-title":"The efficacy and safety of clazakizumab, an anti-interleukin-6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis","volume":"68","author":"Mease","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0124","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3899\/jrheum.111166","article-title":"Psoriasis onset with tocilizumab treatment for rheumatoid arthritis","volume":"39","author":"Wendling","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0125","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/j.1365-2133.2010.10005.x","article-title":"Onset of psoriasis following treatment with tocilizumab","volume":"163","author":"Laurent","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0126","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1159\/000504429","article-title":"Psoriasiform dermatitis developing during treatment of juvenile idiopathic arthritis with tocilizumab","volume":"11","author":"Matsushima","year":"2019","journal-title":"Case Rep Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0127","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cellsig.2018.06.005","article-title":"Role of cAMP and phosphodiesterase signaling in liver health and disease","volume":"49","author":"Wahlang","year":"2018","journal-title":"Cell Signal"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0128","doi-asserted-by":"crossref","first-page":"8253","DOI":"10.1038\/s41598-017-08899-7","article-title":"Coenzyme Q10 improves lipid metabolism and ameliorates obesity by regulating CaMKII-mediated PDE4 inhibition","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0129","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1210\/en.2009-0108","article-title":"Reduced Adiposity and high-fat diet-induced adipose inflammation in mice deficient for phosphodiesterase 4B","volume":"150","author":"Zhang","year":"2009","journal-title":"Endocrinology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0130","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1476-5381.2009.00194.x","article-title":"The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release","volume":"157","author":"Ong","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0131","article-title":"Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis","volume":"12","author":"Ratziu","year":"2014","journal-title":"Clinic Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0132","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 Trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0133","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0134","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/1744666X.2018.1527218","article-title":"Abatacept for the treatment of psoriatic arthritis","volume":"14","author":"Lubrano","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0135","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1704238","article-title":"Preventive CTLA-4-Ig treatment reduces hepatic EGG load and hepatic fibrosis in schistosoma mansoni-infected mice","volume":"2019","author":"Sombetzki","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0136","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-018-1694-9","article-title":"T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis","volume":"20","author":"Boleto","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0137","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/31.7.502","article-title":"Fumaric acid therapy for psoriatic arthritis. A randomized, double-blind, placebo-controlled study","volume":"31","author":"Peeters","year":"1992","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0138","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.14947","article-title":"Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm\u00ae - and placebo-controlled trial (BRIDGE)","volume":"176","author":"Mrowietz","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0139","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/bbrc.1997.6570","article-title":"Dimethylfumarate is an inhibitor of cytokine-induced E-selectin, VCAM-1, and ICAM-1 expression in human endothelial cells","volume":"234","author":"Vandermeeren","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0140","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-4362.1994.tb01070.x","article-title":"IL-1 alpha-induced expression of ICAM-1 on cultured hyperproliferative keratinocytes: suppression by antipsoriatic dimethyl-fumarate","volume":"33","author":"Seb\u00f6k","year":"1994","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0141","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1365-2133.1994.tb08589.x","article-title":"Fumaric acid derivatives evoke a transient increase in intracellular free calcium concentration and inhibit the proliferation of human keratinocytes","volume":"131","author":"Thio","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0142","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/liv.14483","article-title":"Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease","volume":"40","author":"Sangineto","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-2182-0","article-title":"Computational repositioning of dimethyl fumarate for treating alcoholic liver disease","volume":"11","author":"Zhang","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0144","doi-asserted-by":"crossref","first-page":"e22476","DOI":"10.1002\/jbt.22476","article-title":"Dimethyl fumarate protects thioacetamide-induced liver damage in rats: studies on Nrf2, NLRP3, and NF-\u03baB","volume":"34","author":"Dwivedi","year":"2020","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0145","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.lfs.2018.12.013","article-title":"Dimethyl fumarate ameliorates acetaminophen-induced hepatic injury in mice dependent of Nrf-2\/HO-1 pathway","volume":"217","author":"Abdelrahman","year":"2019","journal-title":"Life Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0146","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2147\/PTT.S342911","article-title":"Non-Alcoholic Fatty Liver Disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies","volume":"11","author":"Balak","year":"2021","journal-title":"PTT"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0147","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, Vitamin E, or Placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0148","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0149","doi-asserted-by":"crossref","first-page":"e13377","DOI":"10.1111\/eci.13377","article-title":"Effects of antidiabetic drugs on psoriasis: a meta-analysis","volume":"51","author":"Chi","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0150","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/09546634.2019.1610552","article-title":"Efficacy and safety of pioglitazone for treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"31","author":"Chang","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0151","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0152","first-page":"1","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial","author":"Lin","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0153","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0154","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0155","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0156","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0157","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jdermsci.2011.05.005","article-title":"Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)","volume":"63","author":"Tsai","year":"2011","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0158","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0159","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0160","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0161","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0162","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/bjd.16724","article-title":"Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials","volume":"179","author":"Blauvelt","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0163","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0164","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0165","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0166","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0167","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0168","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0169","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2021-221048","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial","volume":"81","author":"\u00d6st\u00f6r","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/annrheumdis-2021-221019","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial","volume":"81","author":"Kristensen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0171","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0172","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0173","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0174","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0175","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0176","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0177","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0178","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/abbs\/gmt065","article-title":"Neutralization of interleukin-17 attenuates high fat diet-induced non-alcoholic fatty liver disease in mice","volume":"45","author":"Xu","year":"2013","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0179","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0180","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0181","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0182","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0183","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0184","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0185","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0186","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0187","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0188","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","article-title":"Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study","volume":"81","author":"Nakagawa","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0189","doi-asserted-by":"crossref","first-page":"9923","DOI":"10.7150\/thno.45988","article-title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","volume":"10","author":"Zheng","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0190","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0191","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0192","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1136\/ard.2005.040196","article-title":"Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0193","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jaad.2006.07.017","article-title":"A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis","volume":"56","author":"Menter","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0194","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1111\/bjd.12404","article-title":"Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)","volume":"168","author":"Reich","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0195","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/j.1365-2133.2011.10615.x","article-title":"Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1)","volume":"165","author":"Barker","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0196","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","article-title":"Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial","volume":"357","author":"Chaudhari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0197","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0198","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0199","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","article-title":"Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial","volume":"66","author":"Gladman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0200","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2133.2007.08315.x","article-title":"Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)","volume":"158","author":"Saurat","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0201","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0202","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2010.12.005","article-title":"Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0203","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0204","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/acr.22256","article-title":"Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study","volume":"66","author":"Gladman","year":"2014","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0205","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1365-2133.2012.10941.x","article-title":"Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab\u2019 certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension","volume":"167","author":"Reich","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0206","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s13555-017-0208-z","article-title":"Certolizumab pegol in the treatment of psoriasis and psoriatic arthritis: preliminary real-life data","volume":"7","author":"Dattola","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0207","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.3390\/ijms19082199","article-title":"Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-\u03b1 on the liver","volume":"19","author":"Lopetuso","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0208","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0209","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0210","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3899\/jrheum.091093","article-title":"Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis","volume":"37","author":"Mease","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0211","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.jaad.2005.11.1088","article-title":"Efficacy of etanercept in an integrated multistudy database of patients with psoriasis","volume":"54","author":"Gordon","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0212","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1056\/NEJMoa030409","article-title":"Etanercept as monotherapy in patients with psoriasis","volume":"349","author":"Leonardi","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0213","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0214","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0215","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-017-1364-3","article-title":"Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis","volume":"19","author":"Szentpetery","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0216","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0217","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1084\/jem.192.5.681","article-title":"Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells","volume":"192","author":"Abrams","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0218","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00296-020-04564-x","article-title":"Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis","volume":"40","author":"Mease","year":"2020","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0219","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate efficacy in the tight control in psoriatic arthritis study","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0220","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2133.2011.10399.x","article-title":"Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study","volume":"165","author":"Saurat","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0221","article-title":"Methotrexate-associated nonalcoholic fatty liver disease with transaminitis in rheumatoid arthritis","volume":"2014","author":"Sakthiswary","year":"2014","journal-title":"Sci World Jl"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0222","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/pgmj.2005.042200","article-title":"Treatment of non-alcoholic fatty liver disease","volume":"82","author":"Adams","year":"2006","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0223","first-page":"489","article-title":"Liver biopsy findings in patients with rheumatoid arthritis undergoing longterm treatment with methotrexate","volume":"16","author":"Rau","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0224","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1056\/NEJM199101313240501","article-title":"Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial","volume":"324","author":"Ellis","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0225","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1067\/mjd.2001.112400","article-title":"Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study","volume":"44","author":"Ho","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0226","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2165\/00128071-200102010-00007","article-title":"Cyclosporine in severe psoriasis. Results of a meta-analysis in 579 patients","volume":"2","author":"Faerber","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0227","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13543784.2020.1703948","article-title":"Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Ure","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0228","first-page":"1","article-title":"Efficacy of acitretin in severe psoriasis","volume":"8","author":"Geiger","year":"2003","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0229","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/0190-9622(91)70091-F","article-title":"A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study","volume":"24","author":"Murray","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0230","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000351769","article-title":"The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study","volume":"227","author":"Karadag","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0231","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.phrs.2017.04.014","article-title":"The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis","volume":"121","author":"An","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0232","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0233","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13075-019-1901-3","article-title":"Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis","volume":"21","author":"Kavanaugh","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0234","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jaad.2015.09.001","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)","volume":"74","author":"Rich","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0235","series-title":"Efficacy and safety of leflunomide in psoriatic arthritis treatment: a single-arm meta-analysis - Dai -","year":"2019"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0236","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/acr.21848","article-title":"Leflunomide in psoriatic arthritis: results from a large European prospective observational study","volume":"65","author":"Behrens","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0237","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/j.1365-2133.2004.05836.x","article-title":"Leflunomide in the treatment of psoriasis: results of a phase II open trial","volume":"150","author":"Tlacuilo-Parra","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0238","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0239","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000091251","article-title":"Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study","volume":"212","author":"Nash","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/09546634.2015.1050980","article-title":"Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study","volume":"27","author":"Lijnen","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0241","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jdv.15922","article-title":"Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study","volume":"34","author":"van de Kerkhof","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0242","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0243","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0244","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0245","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0246","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0247","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0248","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0249","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003995","article-title":"Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial","volume":"3","author":"Armstrong","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0250","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0251","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.3390\/ijms22052350","article-title":"Treatments for NAFLD: state of Art","volume":"22","author":"Mantovani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0252","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/apt.12352","article-title":"Vitamin E and changes in serum alanine aminotransferase levels in patients with non-alcoholic steatohepatitis","volume":"38","author":"Hoofnagle","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0253","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nut.2008.08.015","article-title":"Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients","volume":"25","author":"Kharaeva","year":"2009","journal-title":"Nutrition"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0254","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1002\/hep.24544","article-title":"Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial","volume":"54","author":"Zein","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0255","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1665-2681(19)31539-X","article-title":"Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial","volume":"10","author":"Van Wagner","year":"2011","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0256","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","article-title":"Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis","volume":"20","author":"Du","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib0257","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1540-9740.2006.05681.x","article-title":"Psoriasis and pentoxifylline: a clinical, histopathologic, and immunohistochemical evaluation","volume":"5","author":"Magela Magalh\u00e3es","year":"2006","journal-title":"Skinmed"},{"key":"10.1016\/j.semarthrit.2023.152165_bib258","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jid.2017.10.024","article-title":"Risk of incident liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis: a population-based study","volume":"138","author":"Ogdie","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.semarthrit.2023.152165_bib259","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/apt.13042","article-title":"The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic","volume":"41","author":"Roberts","year":"2015","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017223000057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:23:37Z","timestamp":1777472617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017223000057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":259,"alternative-id":["S0049017223000057"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152165","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2023.152165","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152165"}}